Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACT Study: Intravitreal Aflibercept for Proliferative Diabetic Retinopathy
NCT01813773Phase 3Completed
- Sponsor
- Ophthalmic Consultants of Long Island
- Start
- Mar 2013
- Primary completion
- Apr 2016
- Modality
- Engineered Antibody Formats, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of aflibercept in proliferative diabetic retinopathy (PDR) (2 arms), sponsored by Ophthalmic Consultants of Long Island. Primary endpoint: Incidence and severity of adverse events at 52 weeks. Started Mar 2013; status: completed.
02
Drugs
aflibercept
03
Conditions
proliferative diabetic retinopathy (PDR)
Beyond the preview
Go deeper on NCT01813773.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01813773.